Free DNA and carcinoembryonic antigen serum levels: An important combination for diagnosis of colorectal cancer

被引:106
作者
Flamini, Emanuela
Mercatali, Laura
Nanni, Oriana
Calistri, Daniele
Nunziatini, Roberta
Zoli, Wainer
Rosetti, Paola
Gardini, Nice
Lattuneddu, Arturo
MariaVerdecchia, Giorgio
Amadori, Dino
机构
[1] Morgagni Pierantoni Hosp, Dept Med Oncol, I-47100 Forli, Italy
[2] Morgagni Pierantoni Hosp, Dept Gen Surg 1, I-47100 Forli, Italy
[3] Morgagni Pierantoni Hosp, Dept Gen Surg 2, I-47100 Forli, Italy
[4] Morgagni Pierantoni Hosp, Chem Clin Anal Lab, I-47100 Forli, Italy
[5] Morgagni Pierantoni Hosp, Blood Transfus Unit, I-47100 Forli, Italy
[6] Ist Oncol Romagnolo, Forli, Italy
[7] Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
关键词
D O I
10.1158/1078-0432.CCR-06-1931
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The identification of new molecular markers for the early detection of colorectal cancer has become an important objective. We compared the sensitivity and specificity of free circulating DNA with that of the more conventional carcinoembryonic antigen (CEA) and evaluated the two markers in combination. Experimental Design: The study was carried out on 75 healthy donors and 75 colorectal cancer patients. Free DNA was determined in serum with quantitative PCR analysis. The diagnostic accuracy of each assay was calculated using receiver operating characteristic (ROC) curves. The diagnostic relevance of the two-marker combination was analyzed by the logistic regression model. Results: Median free DNA concentration was similar to 5-fold higher in patients than in healthy donors (P < 0.001). The area under the ROC curve was 0.86, and when 12.5 ng/mL was used as cutoff, 81.3% sensitivity and 73.3% specificity were observed for the overall series. As CEA and free DNA provided independent diagnostic information, they were also considered in combination. ROC curve analysis of the combined CEA and free DNA algorithms showed a higher diagnostic capacity (area under the ROC curve, 0.92) than that of markers considered singly, with 84% sensitivity and 88% specificity. Conclusions: Free circulating DNA, especially when used in combination with CEA, represents a potentially useful tool for the diagnosis of early-stage colorectal cancer.
引用
收藏
页码:6985 / 6988
页数:4
相关论文
共 28 条
[1]  
Armitage P, 1987, STATISTICAL METHODS, P387
[2]  
Baker MK, 2003, CLIN CANCER RES, V9, P4865
[3]   2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology [J].
Bast, RC ;
Ravdin, P ;
Hayes, DF ;
Bates, S ;
Fritsche, H ;
Jessup, JM ;
Kemeny, N ;
Locker, GY ;
Mennel, RG ;
Somerfield, MR .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1865-1878
[4]   Screening for colorectal cancer - Now and the near future [J].
Bromer, MQ ;
Weinberg, DS .
SEMINARS IN ONCOLOGY, 2005, 32 (01) :3-10
[5]   Detection of colorectal cancer by a quantitative fluorescence determination of DNA amplification in stool [J].
Calistri, D ;
Rengucci, C ;
Lattuneddu, A ;
Francioni, G ;
Polifemo, AM ;
Nanni, O ;
Saragoni, L ;
Monti, F ;
Ravaioli, A ;
Zoli, W ;
Amadori, D .
NEOPLASIA, 2004, 6 (05) :536-540
[6]   Fecal Multiple Molecular Tests to Detect Colorectal Cancer in Stool [J].
Calistri, Daniele ;
Rengucci, Claudia ;
Bocchini, Renato ;
Saragoni, Luca ;
Zoli, Wainer ;
Amadori, Dino .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2003, 1 (05) :377-383
[7]   Estimating the probability of cancer with several tumor markers in patients with colorectal disease [J].
Carpelan-Holmström, M ;
Louhimo, J ;
Stenman, UH ;
Alfthan, H ;
Järvinen, H ;
Haglund, C .
ONCOLOGY, 2004, 66 (04) :296-302
[8]   Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline [J].
Desch, CE ;
Benson, A ;
Somerfield, MR ;
Flynn, PJ ;
Krause, C ;
Loprinzi, CL ;
Minsky, BD ;
Pfister, DG ;
Virgo, KS ;
Petrelli, NJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8512-8519
[9]   Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines [J].
Duffy, MJ ;
van Dalen, A ;
Haglund, C ;
Hansson, L ;
Klapdor, R ;
Lamerz, R ;
Nilsson, O ;
Sturgeon, C ;
Topolcan, O .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (06) :718-727
[10]   Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma [J].
Fernandes, Luis C. ;
Kim, Su B. ;
Matos, Delcio .
WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (05) :645-648